CSF Biomarkers for Alzheimer’s Disease: Levels of β-Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival

Publisher： Karger

E-ISSN： 1421-9824|21|3|131-138

ISSN： 1420-8008

Source： Dementia and Geriatric Cognitive Disorders, Vol.21, Iss.3, 2006-02, pp. : 131-138

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cerebrospinal Fluid Phospho-Tau, Total Tau and β-Amyloid1–42 in the Differentiation between Alzheimer’s Disease and Vascular Dementia

By  

Dementia and Geriatric Cognitive Disorders, Vol. 14, Iss. 4, 2002-11 ,pp. : 183-190

Karger

Access to resources Recommend Favorite

Stability of CSF β-Amyloid1–42 and Tau Levels by APOE Genotype in Alzheimer Patients

By  

Dementia and Geriatric Cognitive Disorders, Vol. 22, Iss. 1, 2006-06 ,pp. : 48-53

Karger

Access to resources Recommend Favorite

Concentrations of Metals, β-Amyloid and Tau-Markers in Cerebrospinal Fluid in Patients with Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 28, Iss. 1, 2009-08 ,pp. : 88-94

Karger

Access to resources Recommend Favorite

Reduction of Phosphorylated Tau during Memantine Treatment of Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 24, Iss. 4, 2007-08 ,pp. : 247-252

Karger

Access to resources Recommend Favorite

Decreased CSF-β-Amyloid 42 in Alzheimer’s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β-Amyloid Induced by Disparate Mechanisms

By  

Dementia and Geriatric Cognitive Disorders, Vol. 13, Iss. 2, 2002-02 ,pp. : 112-118

Karger

Access to resources Recommend Favorite